MedTrace Logo

Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma

NCT05312216 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2023-01-26

No results posted yet for this study

Summary

This is a phase II, open-label study to evaluate the efficacy and safety of Durvalumab plus Lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma.

Conditions

Interventions

DRUG

Durvalumab plus Lenvatinib

Durvalumab: 1500mg, iv.drip, Q4w Lenvatinib: 8mg, QD (body weight \< 60kg) or 12mg, QD (body weight ≥ 60kg) Number of cycle: until subjects withdrawing the informed consent OR progressive disease OR developing unacceptable toxicity events

Sponsors & Collaborators

  • Zhejiang University

    lead OTHER

Principal Investigators

  • Tingbo Liang, PhD · Zhejiang University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-30
Primary Completion
2024-03-31
Completion
2024-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05312216 on ClinicalTrials.gov